South Korea · Delayed Price · Currency is KRW HLB Genex Statistics
Total Valuation
HLB Genex has a market cap or net worth of KRW 88.67 billion. The enterprise value is 112.54 billion.
| Market Cap | 88.67B |
| Enterprise Value | 112.54B |
Important Dates
The next estimated earnings date is Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HLB Genex has 30.16 million shares outstanding. The number of shares has increased by 58.40% in one year.
| Current Share Class | 30.16M |
| Shares Outstanding | 30.16M |
| Shares Change (YoY) | +58.40% |
| Shares Change (QoQ) | -38.42% |
| Owned by Insiders (%) | 12.68% |
| Owned by Institutions (%) | 2.17% |
| Float | 19.42M |
Valuation Ratios
The trailing PE ratio is 4.85.
| PE Ratio | 4.85 |
| Forward PE | n/a |
| PS Ratio | 2.04 |
| PB Ratio | 1.62 |
| P/TBV Ratio | 3.43 |
| P/FCF Ratio | 33.07 |
| P/OCF Ratio | 25.31 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.34, with an EV/FCF ratio of 41.97.
| EV / Earnings | 4.98 |
| EV / Sales | 2.59 |
| EV / EBITDA | 20.34 |
| EV / EBIT | 106.03 |
| EV / FCF | 41.97 |
Financial Position
The company has a current ratio of 0.79, with a Debt / Equity ratio of 0.80.
| Current Ratio | 0.79 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.80 |
| Debt / EBITDA | 7.57 |
| Debt / FCF | 16.23 |
| Interest Coverage | 0.12 |
Financial Efficiency
Return on equity (ROE) is 55.20% and return on invested capital (ROIC) is 2.15%.
| Return on Equity (ROE) | 55.20% |
| Return on Assets (ROA) | 0.57% |
| Return on Invested Capital (ROIC) | 2.15% |
| Return on Capital Employed (ROCE) | 1.75% |
| Weighted Average Cost of Capital (WACC) | 11.01% |
| Revenue Per Employee | 578.27M |
| Profits Per Employee | 301.22M |
| Employee Count | 75 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 4.38 |
Taxes
In the past 12 months, HLB Genex has paid 1.01 billion in taxes.
| Income Tax | 1.01B |
| Effective Tax Rate | 4.21% |
Stock Price Statistics
The stock price has decreased by -17.56% in the last 52 weeks. The beta is 0.05, so HLB Genex's price volatility has been lower than the market average.
| Beta (5Y) | 0.05 |
| 52-Week Price Change | -17.56% |
| 50-Day Moving Average | 2,757.80 |
| 200-Day Moving Average | 2,930.43 |
| Relative Strength Index (RSI) | 52.40 |
| Average Volume (20 Days) | 199,106 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HLB Genex had revenue of KRW 43.37 billion and earned 22.59 billion in profits. Earnings per share was 606.00.
| Revenue | 43.37B |
| Gross Profit | 15.04B |
| Operating Income | 1.28B |
| Pretax Income | 23.90B |
| Net Income | 22.59B |
| EBITDA | 5.75B |
| EBIT | 1.28B |
| Earnings Per Share (EPS) | 606.00 |
Balance Sheet
The company has 33.48 billion in cash and 43.52 billion in debt, with a net cash position of -10.04 billion or -332.98 per share.
| Cash & Cash Equivalents | 33.48B |
| Total Debt | 43.52B |
| Net Cash | -10.04B |
| Net Cash Per Share | -332.98 |
| Equity (Book Value) | 54.75B |
| Book Value Per Share | 1,401.58 |
| Working Capital | -12.90B |
Cash Flow
In the last 12 months, operating cash flow was 3.50 billion and capital expenditures -822.46 million, giving a free cash flow of 2.68 billion.
| Operating Cash Flow | 3.50B |
| Capital Expenditures | -822.46M |
| Depreciation & Amortization | 4.47B |
| Net Borrowing | -10.77B |
| Free Cash Flow | 2.68B |
| FCF Per Share | 88.91 |
Margins
Gross margin is 34.67%, with operating and profit margins of 2.94% and 52.09%.
| Gross Margin | 34.67% |
| Operating Margin | 2.94% |
| Pretax Margin | 55.12% |
| Profit Margin | 52.09% |
| EBITDA Margin | 13.25% |
| EBIT Margin | 2.94% |
| FCF Margin | 6.18% |
Dividends & Yields
HLB Genex does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -58.40% |
| Shareholder Yield | -58.40% |
| Earnings Yield | 25.48% |
| FCF Yield | 3.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 19, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Mar 19, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
HLB Genex has an Altman Z-Score of 1.03 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.03 |
| Piotroski F-Score | 5 |